--- title: "R&D co-funding: expense recognition and investor payments | Altss Blog" description: "Pfizer and Moderna illustrate different timing for development funding, expense relief and contingent investor payments." canonical: "https://altss.com/blog/rd-cofunding-expense-offsets-investor-payments" --- [Altss Research](https://www.linkedin.com/company/altss) 3 min read Updated Nov 14, 2026 Share # R&D co-funding: expense recognition and investor payments Pfizer and Moderna illustrate different timing for development funding, expense relief and contingent investor payments. [Back to blog](https://altss.com/blog) Share [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=) [X](https://x.com/intent/tweet?url=&text=R%26D%20co-funding%3A%20expense%20recognition%20and%20investor%20payments) Copy link R&D expense relief, cash funding and investor receipts follow different triggers. Confusing them distorts company liquidity forecasts and expected fund distributions. ## A ceiling and a contingent payment The [November 11 Pfizer–Blackstone announcement](https://www.blackstone.com/news/press/pfizer-and-blackstone-life-sciences-announce-strategic-funding-agreement-for-obesity-program/) provides for Blackstone-managed funds to pay development costs of up to $1.5 billion through 2028 for investigational berobenatide. Investor milestone payments depend on U.S. approval of monthly injectable monotherapy for chronic weight management and specified commercial sales milestones. Earned payments would be spread over several years. That financing ceiling does not supply a dated investor-return schedule. The announcement leaves milestone amounts undisclosed; a dollar of development support cannot be assigned an assumed repayment date from the headline. ## An expense offset can change without a new advance Moderna’s separate Blackstone arrangement illustrates the accounting distinction. Its [September-quarter Note 5](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000197/mrna-20260930.htm) reports a $69 million R&D expense reduction, recognized proportionally with program costs. Estimates of remaining costs can change recognition. The R&D discussion identifies a $33 million benefit from revising earlier estimates; this is not evidence of an additional cash advance. The note also says September’s first commercial sale triggered entitlement to royalties and sales milestones, yet neither was accrued at September 30. This is a dated accounting observation, not evidence of an investor distribution. Moderna’s terms cannot be transferred to Pfizer’s agreement. ## The liquidity difference in dollars Consider a wholly illustrative company that incurs and pays $40 million of R&D expense this year. Its forecast includes a $10 million expense offset. Assume, solely for this example, that the accounting offset is valid and identical under two cash schedules: one investor transfers $10 million this year; another transfers $6 million now and $4 million next year. These are invented schedules, not estimates for either company. The reported expense after the stipulated offset is $30 million in both cases. Current-year net cash spending is different: $30 million in the first case and $34 million in the second. Treating the expense offset as cash received would understate the second company’s current funding requirement by $4 million. The later receipt does not finance an earlier payment unless another source bridges the gap. Now suppose the same fictional forecast revises the accounting offset to $12 million, with no change to either cash schedule. Reported net expense falls to $28 million. The second company still needs $34 million of current cash. The $2 million pretax improvement has supplied no additional liquidity. This stipulated adjustment demonstrates the arithmetic; it does not reconstruct either issuer’s accounting method. From the investor’s side, the current transfer is an outflow. The company’s expense credit is not a receipt in the investor’s cash-flow forecast. Suppose the fictional agreement separately permits a $15 million payment only after a sales target, with settlement the following year. Reaching that target and receiving the money would still occupy different dates. A fund budgeting cash distributions must use the settlement date, while retaining the possibility that the target is never reached. The underwriting question is when cash moves between counterparties. An expense offset alone cannot determine either party’s spendable balance. Share this article Share ## Related articles [Image: Top 6 Private-Company Deal-Sourcing Databases Used by PE & VC Firms (2026)](https://altss.com/blog/top-6-private-company-deal-sourcing-databases-used-by-pe-and-vc-firms-2025) Private Markets 18 min read ### [Top 6 Private-Company Deal-Sourcing Databases Used by PE & VC Firms (2026)](https://altss.com/blog/top-6-private-company-deal-sourcing-databases-used-by-pe-and-vc-firms-2025) Updated for 2026: the six platforms buy-side teams actually use—PitchBook, S&P Capital IQ Pro, SourceScrub, Grata, CB Insights, and Altss—with ownership ch [Altss Research](https://www.linkedin.com/company/altss) Oct 6, 2025 [Image: A removable report face for Citadel and a separate reveal shield for HBK illustrate restatement versus later disclosure of historical holdings.](https://altss.com/blog/13f-amendments-restatement-new-holdings-citadel-hbk) Private Markets 4 min read ### [13F amendments: replacing a report or adding previously omitted holdings](https://altss.com/blog/13f-amendments-restatement-new-holdings-citadel-hbk) 13F restatements and additions need different dataset operations. Exact Citadel and HBK filings show reporting-period and entry-count boundaries. [Altss Research](https://www.linkedin.com/company/altss) Oct 15, 2026 [Image: A three-date comparison instrument separates June30 holdings, August14 filing and October15 observation,107days after the holdings date.](https://altss.com/blog/13f-october-2026-june-holdings-q3-reporting-deadline) Private Markets 6 min read ### [13F dates in October 2026: June holdings and the Q3 deadline](https://altss.com/blog/13f-october-2026-june-holdings-q3-reporting-deadline) Original Q2 filings and current SEC guidance explain holdings dates, filing dates, the Q3 deadline and what an October 13F observation can establish. [Altss Research](https://www.linkedin.com/company/altss) Oct 15, 2026 ## Canonical URL https://altss.com/blog/rd-cofunding-expense-offsets-investor-payments